DE69730038D1 - Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen - Google Patents

Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen

Info

Publication number
DE69730038D1
DE69730038D1 DE69730038T DE69730038T DE69730038D1 DE 69730038 D1 DE69730038 D1 DE 69730038D1 DE 69730038 T DE69730038 T DE 69730038T DE 69730038 T DE69730038 T DE 69730038T DE 69730038 D1 DE69730038 D1 DE 69730038D1
Authority
DE
Germany
Prior art keywords
fusion proteins
multivalents
monovalents
soluble
mhc class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69730038T
Other languages
English (en)
Other versions
DE69730038T2 (de
Inventor
W Wucherpfennig
L Strominger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of DE69730038D1 publication Critical patent/DE69730038D1/de
Publication of DE69730038T2 publication Critical patent/DE69730038T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69730038T 1996-08-16 1997-08-15 Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen Expired - Fee Related DE69730038T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2407796P 1996-08-16 1996-08-16
US24077P 1996-08-16
PCT/US1997/014503 WO1998006749A2 (en) 1996-08-16 1997-08-15 Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor

Publications (2)

Publication Number Publication Date
DE69730038D1 true DE69730038D1 (de) 2004-09-02
DE69730038T2 DE69730038T2 (de) 2004-11-25

Family

ID=21818743

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69730038T Expired - Fee Related DE69730038T2 (de) 1996-08-16 1997-08-15 Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen

Country Status (11)

Country Link
EP (1) EP0935607B1 (de)
JP (1) JP2000516470A (de)
AT (1) ATE272070T1 (de)
AU (1) AU730457B2 (de)
CA (1) CA2263195A1 (de)
DE (1) DE69730038T2 (de)
DK (1) DK0935607T3 (de)
ES (1) ES2221065T3 (de)
NZ (1) NZ333915A (de)
PT (1) PT935607E (de)
WO (1) WO1998006749A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
EP0889964A1 (de) 1996-03-28 1999-01-13 The Johns Hopkins University Lösliche divalente und multivalente heterodimäre proteinanalogen
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
AU765378B2 (en) * 1998-02-19 2003-09-18 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
FR2778669B1 (fr) * 1998-05-14 2002-06-14 Centre Nat Rech Scient Procede d'expression d'un complexe forme d'au moins un produit du complexe majeur d'histocompatibilite et d'un peptide chez un phage, phages et complexes ainsi obtenus et leurs applications
NZ507887A (en) * 1998-05-19 2002-12-20 Avidex Ltd Soluble T cell receptor
FR2796953B1 (fr) * 1999-07-29 2003-10-10 Centre Nat Rech Scient Proteines recombinantes, et complexes moleculaires derives de ces proteines, analogues a des molecules impliquees dans les reponses immunitaires
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
IL155307A0 (en) 2000-10-10 2003-11-23 Univ Oklahoma Methods for isolating, identifying and purifying peptide ligands and peptide ligands produced thereby
CA2438376A1 (en) * 2000-12-18 2002-08-15 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of antigens and uses thereof
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US7094555B2 (en) 2001-04-05 2006-08-22 Benaroya Research Institute At Virginia Mason Methods of MHC class II epitope mapping, detection of autoimmune T cells and antigens, and autoimmune treatment
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
ES2559763T3 (es) * 2002-09-10 2016-02-15 Affimed Gmbh Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
JP4762717B2 (ja) 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (de) 2007-07-03 2010-03-31 Dako Denmark A/S Zusammengestellte verfahren für die analyse und sortierung von proben
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
GB201002730D0 (en) 2010-02-18 2010-04-07 Uni I Oslo Product
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
AU2013207489A1 (en) * 2012-01-06 2014-08-28 Oregon Health & Science University Partial MHC constructs and methods of use
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US10316075B2 (en) 2013-10-03 2019-06-11 Oregon Health & Science University Recombinant polypeptides comprising MHC class II α1 domains
KR20160077202A (ko) 2013-11-04 2016-07-01 유티아이 리미티드 파트너쉽 지속적 면역요법을 위한 방법 및 조성물
WO2015148960A1 (en) 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
RU2718692C2 (ru) 2014-05-29 2020-04-13 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
US11585806B2 (en) 2014-06-13 2023-02-21 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
BR112017023853A2 (pt) 2015-05-06 2018-07-17 Uti Limited Partnership composições de nanopartícula para terapia sustentada.
KR20180084772A (ko) 2015-10-08 2018-07-25 마크로제닉스, 인크. 암 치료를 위한 조합 치료법
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
KR102646495B1 (ko) * 2016-11-09 2024-03-12 유티아이 리미티드 파트너쉽 재조합 pMHC II형 분자
NZ758485A (en) 2017-04-27 2024-02-23 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
US20220275043A1 (en) * 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
CN112816595A (zh) * 2021-01-06 2021-05-18 海默斯（重庆）医学生物技术有限公司 一种重组角蛋白液体制剂及其纯度检测方法
EP4319813A1 (de) * 2021-04-07 2024-02-14 Repertoire Immune Medicines, Inc. Peptid-mhc-immunglobulinmultimere und verfahren zur verwendung davon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3220593A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
JPH10503379A (ja) * 1994-07-29 1998-03-31 デイド・インターナショナル・インコーポレーテッド Ｍｈｃ複合体およびその用途

Also Published As

Publication number Publication date
PT935607E (pt) 2004-12-31
WO1998006749A2 (en) 1998-02-19
JP2000516470A (ja) 2000-12-12
EP0935607A2 (de) 1999-08-18
AU4072397A (en) 1998-03-06
NZ333915A (en) 2000-11-24
DE69730038T2 (de) 2004-11-25
ES2221065T3 (es) 2004-12-16
WO1998006749A3 (en) 1998-06-11
ATE272070T1 (de) 2004-08-15
EP0935607B1 (de) 2004-07-28
DK0935607T3 (da) 2004-12-06
AU730457B2 (en) 2001-03-08
CA2263195A1 (en) 1998-02-19

Similar Documents

Publication Publication Date Title
DE69730038D1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
DE69514342D1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
DE69933216D1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
ATE96840T1 (de) Fuer die direkte expression von aktiviertem menschlichen protein-c verwendbare vektoren und zusammensetzungen.
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
DK0719340T3 (da) Klonet glutaminsyre-decarboxylase
CA2045869A1 (en) Fusion proteins with immunoglobulin portions, the preparation and use thereof
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
UA26855C2 (uk) Фармацевтичhа композиція, яка регулює гематопоез
ATE328068T1 (de) Papillomavirus vakzine
ES2063515T3 (es) Ifn-alfa o-glucosilados.
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
BG102362A (en) New derivatives of amino acids, their preparation and application
ATE218616T1 (de) Humanes zirkulierendes cytokin cc-1
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
TR199800575T1 (en) Kemokin �-8'in k�sa formlar�.
DE3751834D1 (de) Selbstantigen der primären lebercirrhose
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
EA199801032A1 (ru) Белки zona pellucida для контрацепции
AU132015S (en) Pants

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee